Effect of enhanced peer PrEP referral with HIV self-testing delivery among young Kenyan women: A randomized controlled trial of peer networks.
(2026 Mar)
PLoS Med 23(3): e1005023
Ortblad KF, Wairimu N, Culquichicon C, Njeru I, Malen RC, Reedy AM, Ekwunife O, McGowan M, Mwangi M, Muthoni A, Kiboi D, Njoroge S, Gao F, Baeten JM, Ngure K

Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study.
(2026 Mar)
Lancet Microbe 7(3): 101283
Ogbuagu O, Gaur A, McMahon JH, Gorgos L, Morales-Ramirez JO, Workowski K, Brunetta J, Mponponsuo K, Collins SE, VanderVeen LA, Zhang N, Huang H, Baeten JM, Eron J

Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.
(2026 Feb)
Ann Intern Med 179(2): 168-176
Colson AE, Crofoot GE, Ruane PJ, Ramgopal MN, Dretler AW, Nahass RG, Sinclair GI, Berhe M, Roberts A, Applin S, Brinson C, Jayaweera D, Workowski KA, Shihadeh F, Liu SY, Klopfer S, Llamoso C, Madera S, Dvory-Sobol H, Rhee MS, Rhee EG, Baeten JM, Eron JJ

Trichomonas vaginalis Among Cisgender Women Taking Doxycycline Postexposure Prophylaxis.
(2026 Feb 18)
J Infect Dis 233(2): 411-415
Sesay FA, Oware K, Violette LR, Donnell D, Odoyo JB, Omollo V, Mogaka FO, McClelland RS, Balkus JE, Bukusi EA, Baeten JM, Stewart J

Adherence thresholds for emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis against HIV acquisition in cisgender women: A randomized directly observed dosing study.
(2025 Sep)
PLoS Med 22(9): e1004732
Mugwanya KK, Saina M, Mugo NR, MaWhinney S, Morrow M, Schaafsma TT, Donnell D, Glidden DV, Ngure K, Brown CE, Rechkina EA, Chohan BH, Wu L, Hill E, Koome E, Akelo N, Mbaire S, Morrison SA, Kibatha M, Njeru I, Muriithi M, Coppinger C, Bushman L, Baeten JM, Anderson PL, Women Benchmark Study Team